Oncology-Focused Biotech Selects Medidata
Start-up biotech selects Medidata Rave for Phase I and II trials of its investigational compound to address solid tumors and blood cancers.
Forty Seven Inc., a Stanford University start-up biotech specializing in cancer immunotherapy, will use Medidata’s electronic data capture, management and reporting system Medidata Rave in two of its upcoming Phase I and Phase II trials. Forty Seven takes its name from CD47 tumor cell protein that its lead molecule, Hu5F9-G4-an experimental monoclonal cancer drug-to be tested in solid tumor and blood cancers.
Read the full release.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
